A carregar...
SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study
BACKGROUND: Clostridium difficile infections (CDI) are an “urgent threat,” but there are no approved drugs or vaccines to prevent new onset CDI. SYN-004 (ribaxamase) is a β-lactamase designed to be orally administered with IV β-lactam antibiotics and remain localized in the intestine to degrade anti...
Na minha lista:
| Publicado no: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5631845/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx162.029 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|